Most cited papers from Athenex (United States)

Athenex (United States)

What are the most cited papers from Athenex (United States)?

The most cited paper from Athenex (United States) is "Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors" (Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al., 2000), with 1,284 citations. Next come "Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia" (897) and "Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial" (420).

Published TypeFieldAccessCitations

Showing 50 of 89 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics	Oct 2000	1,284
2	Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia Brian J. Druker, Nicholas Lydon · Journal of Clinical Investigation Open access	2000	897
3	Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Manfred Westphal, Zvi Ram, V. Riddle et al. · Acta Neurochirurgica	15 Feb 2006	420
4	Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis Andrew Blauvelt, Steven E. Kempers, Edward L. Lain et al. · New England Journal of Medicine	10 Feb 2021	168
5	Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361) Michael P. Smolinski, Yahao Bu, James L. Clements et al. · Journal of Medicinal Chemistry Open access	4 Apr 2018	101
6	Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2Rγnull Mice Michelle R. Simpson-Abelson, Gregory F. Sonnenberg, Hiroshi Takita et al. · The Journal of Immunology	May 2008	94
7	SSeCKS/Gravin/AKAP12 Inhibits Cancer Cell Invasiveness and Chemotaxis by Suppressing a Protein Kinase C- Raf/MEK/ERK Pathway Bing Su, Yahao Bu, David Engelberg et al. · Journal of Biological Chemistry Open access	16 Dec 2009	87
8	A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin Melencio Posadas et al. · Cancer Chemotherapy and Pharmacology Open access	12 Jan 2013	79
9	Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations Sameer Urgaonkar, Kamil Nosol, Ahmed Mohammed Said et al. · Journal of Medicinal Chemistry Open access	20 Dec 2021	71
10	KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer Muralidharan Anbalagan, Latonya Carrier, Seth Glodowski et al. · Breast Cancer Research and Treatment	20 Apr 2011	65
11	Thiazolyl N-benzyl-substituted acetamide derivatives: Synthesis, Src kinase inhibitory and anticancer activities Asal Fallah‐Tafti, Alireza Foroumadi, Rakesh Kumar Tiwari et al. · European Journal of Medicinal Chemistry Open access	7 Aug 2011	65
12	Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro Grace Lau, Gillian M.G. Lau, Guoliang Yu et al. · Digestive Diseases and Sciences	31 Oct 2008	62
13	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor Michael P. Smolinski, Sameer Urgaonkar, Laura B. Pitzonka et al. · Journal of Medicinal Chemistry Open access	17 Mar 2021	56
14	Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma Qiuzhong Pan et al. · Cell Reports Medicine Open access	Aug 2023	54
15	Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts Muralidharan Anbalagan, Alaa Mohammed Ali, Ryan K. Jones et al. · Molecular Cancer Therapeutics Open access	11 Jul 2012	47
16	Targeting Src and Tubulin in Mucinous Ovarian Carcinoma Tao Liu et al. · Clinical Cancer Research Open access	7 Oct 2013	41
17	A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies Aung Naing, Roger B. Cohen, Grace Kho Dy et al. · Investigational New Drugs	29 Jan 2013	41
18	Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity Steven X. Xu, Min Yuan, Hao Zhu et al. · British Journal of Clinical Pharmacology Open access	9 Mar 2018	37
19	Low Somatic Sodium Conductance Enhances Action Potential Precision in Time-Coding Auditory Neurons Yang Yang, Bina Ramamurthy, Andreas Neef et al. · Journal of Neuroscience Open access	23 Nov 2016	37
20	A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients Wen Wee Ma, Hao Xie, Gerald Fetterly et al. · American Journal of Clinical Oncology Open access	8 Nov 2018	33
21	An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model Chengjian Tu, Jun‐Xu Li, Yahao Bu et al. · Journal of Proteomics Open access	7 Sep 2012	32
22	Great balls of fire Stanley Singer · Nature	Mar 1991	32
23	Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial Yi‐Wen Huang, Albert Qin, Jane W. S. Fang et al. · British Journal of Clinical Pharmacology Open access	15 Dec 2021	31
24	Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis Seongyeong Kim, Ahrum Min, Kyung-Hun Lee et al. · Cancer Research and Treatment Open access	6 Oct 2016	29
25	Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease Thomas F. Conway, Laura A. Hammer, Stacia Furtado et al. · Journal of Crohn s and Colitis Open access	18 May 2015	28
26	Sebum: Analysis by Infrared Spectroscopy Arthur S. Anderson, James E. Fulton · Journal of Investigative Dermatology Open access	Mar 1973	28
27	Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer Hope S. Rugo, Gerardo A. Umanzor, Francisco Barrios et al. · Journal of Clinical Oncology Open access	20 Jul 2022	25
28	Novel pyrrolopyrimidine derivatives: design, synthesis, molecular docking, molecular simulations and biological evaluations as antioxidant and anti-inflammatory agents Amira Ibrahim Sayed, Yara E. Mansour, Mohamed Abdel-Shakur Ali et al. · Journal of Enzyme Inhibition and Medicinal Chemistry Open access	27 Jun 2022	25
29	Ionene polymers. III. Dicationic crosslinking agents (1) Alan Rembaum, S. J. Singer, Hendrik Keyzer · Journal of Polymer Science Part B Polymer Letters	May 1969	25
30	Characterization of Cytokine-Encapsulated Controlled-Release Microsphere Adjuvants Atima Sharma, Carl M. Harper, Laura A. Hammer et al. · Cancer Biotherapy and Radiopharmaceuticals	Dec 2004	25
31	Looking for a humane interface Jef Raskin · Communications of the ACM Open access	Feb 1997	25
32	Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment Vaishali Sahasrabudhe, Steven G. Terra, Anne Hickman et al. · Clinical Therapeutics	15 Sep 2018	24
33	Role for transcription factor TFII‐I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src Yahao Bu, Lingqiu Gao, Irwin H. Gelman · International Journal of Cancer Open access	21 Jun 2010	20
34	HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model Jianming Wu, Betty Yuen Kwan Law, Vincent Kam Wai Wong et al. · Cancer Biology and Medicine Open access	2020	17
35	Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression Muralidharan Anbalagan, Mei Sheng, Brian P. Fleischer et al. · Molecular Cancer Research Open access	27 Jul 2017	16
36	Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment Kuo-Ming Yu, Tammy Pui-shi Pang, Murray J. Cutler et al. · Life Sciences	28 Oct 2020	15
37	Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study Christopher C. Jackson, Tak Hung, Eva Segelov et al. · British Journal of Clinical Pharmacology Open access	8 May 2021	14
38	KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma Michael J. Ciesielski, Yahao Bu, Stephan A. Munich et al. · Journal of Neuro-Oncology	20 Sep 2018	14
39	Ball lightning—the scientific effort Stanley Singer · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences	4 Dec 2001	13
40	Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers Naglaa Ahmed, Mosaad Sayed Mohamed, Samir M. Awad et al. · Journal of Enzyme Inhibition and Medicinal Chemistry Open access	13 Feb 2024	12
41	In Vitro Skin Permeation and Bioassay of Chlorhexidine Phosphanilate, a New Antimicrobial Agent Jonas C. T. Wang, Robert R. Williams, Lotte Wang et al. · Pharmaceutical Research	Oct 1990	12
42	A chemosensing approach for the detection of Cu2+ ion using benzothiazole based probe and its applications in anticancer studies S. Dhanapal, F. Riyazur Rahman, R. Veerasamy et al. · Inorganica Chimica Acta	5 Feb 2025	11
43	A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies Wen Wee Ma, Jing Li, Nilofer Saba Azad et al. · Cancer Chemotherapy and Pharmacology	22 Jun 2022	10
44	Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis Regina Yavel, J. Scott Overcash, David L. Cutler et al. · Clinical Pharmacology in Drug Development	16 Nov 2021	8
45	Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real-World Evidence Analysis Bruce A. Feinberg, Jonathan Karl Kish, Igoni Dokubo et al. · The Oncologist Open access	17 Jan 2020	8
46	Potent and selective in vitro and in vivo inhibition of tumor proliferation by KXO1, a novel non-ATP competitive Src inhibitor David G Hangauer, Irwin H. Gelman, Lyn M. Dyster et al. · Cancer Research	May 2007	8
47	A genetic component in human lysosomal enzyme excretion Kenneth Paigen, Janice Peterson, Elizabeth Ward · Biochemical Genetics	Jun 1984	8
48	A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia Margaret T. Kasner, Molly B. Halloran, Jonathan Pan et al. · Investigational New Drugs	17 May 2022	7
49	Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease Laura A. Hammer, Stacia Furtado, Edith Mathiowitz et al. · World Journal of Gastrointestinal Pharmacology and Therapeutics Open access	5 Nov 2020	7
50	Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results Jin‐Bon Hong, Po‐Yuan Wu, Albert Qin et al. · Pharmaceutics Open access	11 Oct 2022	6

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.